Tao J, Bian X, Zhou J, Zhang M
Cytojournal. 2024; 21:29.
PMID: 39391208
PMC: 11464998.
DOI: 10.25259/Cytojournal_36_2024.
Chen X, Pan Y, Wang Q, Ren C, Li M, Hao X
Front Endocrinol (Lausanne). 2023; 14:1225033.
PMID: 38027160
PMC: 10644304.
DOI: 10.3389/fendo.2023.1225033.
Koinis F, Zafeiriou Z, Messaritakis I, Katsaounis P, Koumarianou A, Kontopodis E
Cancers (Basel). 2023; 15(18).
PMID: 37760481
PMC: 10527446.
DOI: 10.3390/cancers15184511.
Kurniali P, Storandt M, Jin Z
J Pers Med. 2023; 13(4).
PMID: 37109080
PMC: 10145886.
DOI: 10.3390/jpm13040694.
Cieslikowski W, Milecki P, Swierczewska M, Ida A, Kasperczak M, Jankowiak A
J Pers Med. 2023; 13(4).
PMID: 37108995
PMC: 10144132.
DOI: 10.3390/jpm13040608.
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies C, Guo T, Burke E, Stankiewicz E, Xu L, Mao X
Front Oncol. 2023; 12:1060864.
PMID: 36727071
PMC: 9885040.
DOI: 10.3389/fonc.2022.1060864.
Protein degradation: expanding the toolbox to restrain cancer drug resistance.
Ming H, Li B, Jiang J, Qin S, Nice E, He W
J Hematol Oncol. 2023; 16(1):6.
PMID: 36694209
PMC: 9872387.
DOI: 10.1186/s13045-023-01398-5.
A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.
Enikeev D, Morozov A, Babaevskaya D, Bazarkin A, Malavaud B
Cancers (Basel). 2022; 14(15).
PMID: 35954464
PMC: 9367494.
DOI: 10.3390/cancers14153802.
[A Rare Case of Extremely High Counts of EpCAM Circulating Tumor Cells and Circulating Tumor Microemboli Detected in a Patient with Small Cell Lung Cancer].
Jiang T, Li H, Li Y
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022; 53(4):711-715.
PMID: 35871746
PMC: 10409470.
DOI: 10.12182/20220760107.
Bone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report.
Li K, Du Y, Yang D, Yu X, Zhang X, Li Y
World J Clin Cases. 2022; 10(15):4985-4990.
PMID: 35801020
PMC: 9198870.
DOI: 10.12998/wjcc.v10.i15.4985.
Molecular mechanisms of docetaxel resistance in prostate cancer.
Sekino Y, Teishima J
Cancer Drug Resist. 2022; 3(4):676-685.
PMID: 35582222
PMC: 8992564.
DOI: 10.20517/cdr.2020.37.
Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy.
Yang G, Xie J, Zhang S, Gu W, Yuan J, Wang R
Front Oncol. 2022; 11:812549.
PMID: 35127528
PMC: 8810514.
DOI: 10.3389/fonc.2021.812549.
Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management.
Cieslikowski W, Antczak A, Nowicki M, Zabel M, Budna-Tukan J
Biomedicines. 2021; 9(9).
PMID: 34572366
PMC: 8471111.
DOI: 10.3390/biomedicines9091179.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Lozano R, Lorente D, Aragon I, Romero-Laorden N, Nombela P, Mateo J
Cancers (Basel). 2021; 13(10).
PMID: 34066080
PMC: 8151844.
DOI: 10.3390/cancers13102334.
Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment.
Yang M, Zhang X, Guo L, Liu X, Wu J, Zhu H
Biomed Res Int. 2021; 2021:6230826.
PMID: 33506020
PMC: 7814947.
DOI: 10.1155/2021/6230826.
Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer.
Wang C, Zhang Z, Chong W, Luo R, Myers R, Gu J
Cancers (Basel). 2021; 13(2).
PMID: 33450815
PMC: 7828213.
DOI: 10.3390/cancers13020268.
Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients.
Theil G, Fornara P, Bialek J
Cancers (Basel). 2020; 12(12).
PMID: 33333999
PMC: 7765455.
DOI: 10.3390/cancers12123782.
Clinical utility of circulating tumor cells: an update.
Vasseur A, Kiavue N, Bidard F, Pierga J, Cabel L
Mol Oncol. 2020; 15(6):1647-1666.
PMID: 33289351
PMC: 8169442.
DOI: 10.1002/1878-0261.12869.
The biology and clinical potential of circulating tumor cells.
Lozar T, Gersak K, Cemazar M, Grasic Kuhar C, Jesenko T
Radiol Oncol. 2019; 53(2):131-147.
PMID: 31104002
PMC: 6572494.
DOI: 10.2478/raon-2019-0024.
Nanoparticles as theranostic vehicles in prostate cancer.
Morales-Barrera R, Suarez C, Mateo J, Gonzalez M, Carles J
Ann Transl Med. 2019; 7(Suppl 1):S29.
PMID: 31032309
PMC: 6462597.
DOI: 10.21037/atm.2019.01.77.
